BofA Securities Reiterates Neutral Rating on Cytokinetics (CYTK)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
Go back to BofA Securities Reiterates Neutral Rating on Cytokinetics (CYTK)
September 9, 2024 12:11 PM EDT
Goldman Sachs analyst Paul Choi reiterated a Neutral rating and $60.00 price target on Cytokinetics (NASDAQ: CYTK).
The analyst comments "Overall consistent results support advancing CK-586 into Phase 2 studies though greater conviction remains elusive for now. We reviewed the results of a Phase 1... More
September 7, 2024 8:00 PM EDT
With only around 4 months left for 2024 to end, Piper Sandler analysts have identified 22 biotechnology stocks with key data catalysts/ approvals in 2025.
We looked at our coverage to look for data and approval driven catalysts that provide buying opportunities as the year is coming to a close, the firm told its clients in a note.
Among stocks with a market cap of over $1 billion, the firm identified 10 names.
1. Cytokinetics Inc. (NASDAQ: CYTK): With rolling submission expected to finish in 3Q24, we calculate potential aficamten oHCM... More
